Recorded fact · drug.label_indication
drug.label_indication for trametinib-dimethyl-sulfoxide|melanoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact fdb9ea05 resolves to.
The record
| Fact id | fdb9ea050f0da9d712bf644d |
|---|---|
| Entity | drug: trametinib-dimethyl-sulfoxide|melanoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260507 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: e265709f160901978fcabf0894411589945dad14ca68f44c8b1bd928a4a0c6ce.
The value
{
"ingredient": "Trametinib Dimethyl Sulfoxide",
"conditionId": "melanoma",
"conditionName": "Melanoma",
"matchedAlias": "melanoma",
"context": "indication",
"brand": "Mekinist",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "0002ad27-779d-42ab-83b5-bc65453412a1",
"labelEffectiveTime": "20260507",
"labelsRead": 2,
"labelsNaming": 2,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 6e7395e0a2360f6d0e9ee1b9085a5ffd4b29fd12f12451f32f40941dc56832b8.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.